Shareholder urges Spacelabs to sell:
This article was originally published in Clinica
A shareholder with a 13% share in Spacelabs Medical has written to the company urging it to sell the company and, in particular, to consider Cardiac Science's recent $15 per share offer. Shareholder Tweedy, Brown, an investment adviser company, cites Spacelab's continued inadequate profitability, the marked deterioration in its financial strength, as well as questioning its competitiveness. Cardiac Science made its unsolicited bid in late November (see Clinica No 937, p 11).